ASH 2022 | Updated results from the MOMENTUM trial
Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an update on the MOMENTUM study (NCT04173494) comparing the efficacy of momelotinib to danazol in patients with myelofibrosis (MF) who have previously been treated with ruxolitinib. The results suggest that the benefits of momelotinib in terms of anemia and symptom improvement are durable. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NS Pharma: Research Funding; AstraZeneca: Research Funding; ItalPharma: Research Funding; Novartis: Consultancy, Research Funding; Incyte: Consultancy, Research Funding; Promedior: Research Funding; CTI BioPharma Corp.: Research Funding; Gilead: Research Funding; Sierra Oncology: Consultancy, Research Funding; Roche: Research Funding; Protagonist Therapeutics: Research Funding; PharmaEssentia: Research Funding; Blueprints Medicines Corp.: Research Funding; Celgene: Consultancy, Research Funding; Genentech: Research Funding; Pragmatist: Consultancy; Constellation Pharmaceuticals: Consultancy.
